Anti-tumor effect of innovative tumor treatment device OM-100 through enhancing anti-PD-1 immunotherapy in glioblastoma growth
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Anti-tumor effect of innovative tumor treatment device OM-100 through enhancing anti-PD-1 immunotherapy in glioblastoma growth ; volume:14 ; number:1 ; day:8 ; month:8 ; year:2024 ; pages:1-10 ; date:12.2024
Scientific reports ; 14, Heft 1 (8.8.2024), 1-10, 12.2024
- Urheber
-
Yan, Zhaoxian
Huang, Lifa
Zhang, Xin
Yu, Xinyan
Huang, Rui
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-024-67437-4
- URN
-
urn:nbn:de:101:1-2410272119148.592761370937
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 07:36 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Yan, Zhaoxian
- Huang, Lifa
- Zhang, Xin
- Yu, Xinyan
- Huang, Rui
- SpringerLink (Online service)
Ähnliche Objekte (12)
Targeting CD73 limits tumor progression and enhances anti-tumor activity of anti-PD-1 therapy in intrahepatic cholangiocarcinoma
Anti-PD-1 antibody armored γδ T cells enhance anti-tumor efficacy in ovarian cancer
Proactive over reactive: the snare-based pretraction method improving the full-thickness resection of a large gastrointestinal stromal tumor
Targeted Anti‐Tumor Immunotherapy Using Tumor Infiltrating Cells
TH9 cells in anti-tumor immunity
Reversible acute blindness in suspected metformin-associated lactic acidosis: a case report
Targeting tumor cells with antibodies enhances anti-tumor immunity
Melatonin: an anti-tumor agent for osteosarcoma
Golimumab: A Novel Anti-Tumor Necrosis Factor
Tumor ablation induced anti-tumor immunity: destruction of the tumor in situ with the aim to evoke a robust anti-tumor immune response
Inducible localized delivery of an anti-PD-1 scFv enhances anti-tumor activity of ROR1 CAR-T cells in TNBC
Estrogen/ER in anti-tumor immunity regulation to tumor cell and tumor microenvironment
Targeting CD73 limits tumor progression and enhances anti-tumor activity of anti-PD-1 therapy in intrahepatic cholangiocarcinoma
Anti-PD-1 antibody armored γδ T cells enhance anti-tumor efficacy in ovarian cancer
Proactive over reactive: the snare-based pretraction method improving the full-thickness resection of a large gastrointestinal stromal tumor
Targeted Anti‐Tumor Immunotherapy Using Tumor Infiltrating Cells
TH9 cells in anti-tumor immunity
Reversible acute blindness in suspected metformin-associated lactic acidosis: a case report
Targeting tumor cells with antibodies enhances anti-tumor immunity
Melatonin: an anti-tumor agent for osteosarcoma
Golimumab: A Novel Anti-Tumor Necrosis Factor
Tumor ablation induced anti-tumor immunity: destruction of the tumor in situ with the aim to evoke a robust anti-tumor immune response
Inducible localized delivery of an anti-PD-1 scFv enhances anti-tumor activity of ROR1 CAR-T cells in TNBC
Estrogen/ER in anti-tumor immunity regulation to tumor cell and tumor microenvironment
Targeting CD73 limits tumor progression and enhances anti-tumor activity of anti-PD-1 therapy in intrahepatic cholangiocarcinoma
Anti-PD-1 antibody armored γδ T cells enhance anti-tumor efficacy in ovarian cancer
Proactive over reactive: the snare-based pretraction method improving the full-thickness resection of a large gastrointestinal stromal tumor
Targeted Anti‐Tumor Immunotherapy Using Tumor Infiltrating Cells
TH9 cells in anti-tumor immunity
Reversible acute blindness in suspected metformin-associated lactic acidosis: a case report
Targeting tumor cells with antibodies enhances anti-tumor immunity
Melatonin: an anti-tumor agent for osteosarcoma
Golimumab: A Novel Anti-Tumor Necrosis Factor
Tumor ablation induced anti-tumor immunity: destruction of the tumor in situ with the aim to evoke a robust anti-tumor immune response
Inducible localized delivery of an anti-PD-1 scFv enhances anti-tumor activity of ROR1 CAR-T cells in TNBC